Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Jacob G. Robison, MD, Professor of Vascular Surgery, Medical University of South Carolina, discusses reversal of flow, a technique where particles that occur at the time of balloon…
Jacob G. Robison, MD, Professor of Vascular Surgery, Medical University of South Carolina, discusses abdominal aortic aneurysm repair using stent grafts. These devices must be used in an…
NEW YORK (Reuters Health) – For patients with multiple myeloma who are not eligible for autologous stem-cell transplantation, a four-drug combination regimen is promising. Adding thalidomide to bortezomib-melphalan-prednisone,…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
NEW YORK (Reuters Health) – Patients at high risk for pancreatic cancer can be effectively screened with imaging studies and genetic testing, allowing curable neoplasm to be identified…
NEW YORK (Reuters Health) – Adding interferon alpha-2b and megadose vitamins to treatment with intravesical BCG does not improve outcomes in patients with non-muscle invasive bladder cancer. In…
NEW YORK (Reuters Health) – The tyrosine-kinase inhibitor pazopanib seems to be a promising option for treating progressive metastatic differentiated thyroid cancer that is unresponsive to radioiodine therapy,…
NEW YORK (Reuters Health) – Response rates are higher when bortezomib plus dexamethasone rather than vincristine plus doxorubicin plus dexamethasone (VAD) is used as induction therapy before stem-cell…
NEW YORK (Reuters Health) – Men whose baseline PSA is less than 2.0 ng/mL are unlikely to benefit from further screening for prostate cancer, according to findings reported…
